Skip to main content
Top
Published in: International Journal of Legal Medicine 1/2014

01-01-2014 | Case Report

Driving under the influence of synthetic cannabinoids (“Spice”): a case series

Authors: Frank Musshoff, Burkhard Madea, Gerhard Kernbach-Wighton, Wolfgang Bicker, Stefan Kneisel, Melanie Hutter, Volker Auwärter

Published in: International Journal of Legal Medicine | Issue 1/2014

Login to get access

Abstract

Recreational use of synthetic cannabinoid receptor agonists—so-called “Spice” products—became very popular during the last few years. Several reports on clinical symptoms and poisonings were published. Unfortunately, most of these reports do not contain any analytical data on synthetic cannabinoids in body fluids, and no or only a limited number of cases were reported concerning driving under the influence (DUI) of this kind of drugs. In this article, several cases of DUI of synthetic cannabinoids (AM-2201, JWH-018, JWH-019, JWH-122, JWH-210, JWH-307, MAM-2201 (JWH-122 5-fluoropentyl derivative), and UR-144) are presented, focusing on analytical results and signs of impairment documented by the police or the physicians who had taken the blood sample from the suspects. Consumption of synthetic cannabinoids can lead to impairment similar to typical performance deficits caused by cannabis use which are not compatible with safe driving. These deficits include centrally sedating effects and impairment of fine motor skills necessary for keeping the vehicle on track. Police as well as forensic toxicologists and other groups should become familiar with the effects of synthetic cannabinoid use, and be aware of the fact that drug users may shift to these “legal” alternatives due to their nondetectability by commonly used drug screening tests based on antibodies. Sophisticated screening procedures covering the complete range of available compounds or their metabolites have to be developed for both blood/serum and urine testing.
Literature
1.
go back to reference Pertwee R (2005) Cannabinoids. Handb. Exp. Pharm, 168. Springer, Heidelberg, Germany Pertwee R (2005) Cannabinoids. Handb. Exp. Pharm, 168. Springer, Heidelberg, Germany
2.
go back to reference Auwärter V, Kneisel S, Hutter M, Thierauf A (2012) Synthetische Cannabinoide - Forensische Relevanz und Interpretation analytischer Befunde. Rechtsmed 22:259–271CrossRef Auwärter V, Kneisel S, Hutter M, Thierauf A (2012) Synthetische Cannabinoide - Forensische Relevanz und Interpretation analytischer Befunde. Rechtsmed 22:259–271CrossRef
3.
go back to reference Werse B, Müller O, Schell C, Morgenstern C (2011) Jahresbericht MoSyD. Drogentrends in Frankfurt am Main 2010. Centre for Drug Research. Werse B, Müller O, Schell C, Morgenstern C (2011) Jahresbericht MoSyD. Drogentrends in Frankfurt am Main 2010. Centre for Drug Research.
4.
go back to reference Ashton JC, Wright JL, Mc Partland JM, Tyndall JD (2008) Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists. Curr Med Chem 15:1428–1443PubMedCrossRef Ashton JC, Wright JL, Mc Partland JM, Tyndall JD (2008) Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists. Curr Med Chem 15:1428–1443PubMedCrossRef
5.
go back to reference Pertwee RG (1999) Pharmacology of cannabinoid receptor ligands. Curr Med Chem 6:635–664PubMed Pertwee RG (1999) Pharmacology of cannabinoid receptor ligands. Curr Med Chem 6:635–664PubMed
6.
go back to reference Pertwee RG (2000) Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery, and development. Expert Opin Investig Drugs 9:1553–1571PubMedCrossRef Pertwee RG (2000) Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery, and development. Expert Opin Investig Drugs 9:1553–1571PubMedCrossRef
7.
go back to reference Pertwee RG, Ross RA (2002) Cannabinoid receptors and their ligands. Prostaglandins Leukot. Essent Fat Acids 66:101–121CrossRef Pertwee RG, Ross RA (2002) Cannabinoid receptors and their ligands. Prostaglandins Leukot. Essent Fat Acids 66:101–121CrossRef
8.
go back to reference Pertwee RG (2006) The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes (Lond) 30(Suppl 1):S13–S18CrossRef Pertwee RG (2006) The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes (Lond) 30(Suppl 1):S13–S18CrossRef
9.
go back to reference Pertwee RG (2008) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol, and delta9-tetrahydrocannabivarin. Br J Pharmacol 153:199–215PubMedCrossRef Pertwee RG (2008) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol, and delta9-tetrahydrocannabivarin. Br J Pharmacol 153:199–215PubMedCrossRef
10.
go back to reference McCarberg BH, Barkin RL (2007) The future of cannabinoids as analgesic agents: a pharmacologic, pharmacokinetic, and pharmacodynamic overview. Am J Ther 14:475–483PubMedCrossRef McCarberg BH, Barkin RL (2007) The future of cannabinoids as analgesic agents: a pharmacologic, pharmacokinetic, and pharmacodynamic overview. Am J Ther 14:475–483PubMedCrossRef
11.
go back to reference Auwärter V, Dresen S, Weinmann W, Müller M, Pütz M, Ferreiros N (2009) “Spice” and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom 44:832–837PubMedCrossRef Auwärter V, Dresen S, Weinmann W, Müller M, Pütz M, Ferreiros N (2009) “Spice” and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom 44:832–837PubMedCrossRef
12.
go back to reference Lindigkeit R, Boehme A, Eiserloh I, Luebbecke M, Wiggermann M, Ernst L, Beuerle T (2009) Spice: a never ending story? Forensic Sci Int 191:58–63PubMedCrossRef Lindigkeit R, Boehme A, Eiserloh I, Luebbecke M, Wiggermann M, Ernst L, Beuerle T (2009) Spice: a never ending story? Forensic Sci Int 191:58–63PubMedCrossRef
13.
go back to reference Dresen S, Ferreiros N, Pütz M, Westphal F, Zimmermann R, Auwärter V (2010) Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds. J Mass Spectrom 45:1186–1194PubMedCrossRef Dresen S, Ferreiros N, Pütz M, Westphal F, Zimmermann R, Auwärter V (2010) Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds. J Mass Spectrom 45:1186–1194PubMedCrossRef
14.
go back to reference Hudson S, Ramsey J (2011) The emergence and analysis of synthetic cannabinoids. Drug Test Anal 3:466–478PubMedCrossRef Hudson S, Ramsey J (2011) The emergence and analysis of synthetic cannabinoids. Drug Test Anal 3:466–478PubMedCrossRef
15.
go back to reference Simolka K, Lindigkeit R, Schiebel HM, Papke U, Ernst L, Beuerle T (2012) Analysis of synthetic cannabinoids in "spice-like" herbal highs: snapshot of the German market in summer 2011. Anal Bioanal Chem 404:157–171PubMedCrossRef Simolka K, Lindigkeit R, Schiebel HM, Papke U, Ernst L, Beuerle T (2012) Analysis of synthetic cannabinoids in "spice-like" herbal highs: snapshot of the German market in summer 2011. Anal Bioanal Chem 404:157–171PubMedCrossRef
16.
go back to reference Moosmann B, Kneisel S, Girreser U, Brecht V, Westphal F, Auwärter V (2012) Separation and structural characterization of the synthetic cannabinoids JWH-412 and 1-[(5-fluoropentyl)-1H-indol-3yl]-(4-methylnaphthalen-1-yl)methanone using GC-MS NMR analysis and a flash chromatography system. Forensic Sci Int 220:e17–e22PubMedCrossRef Moosmann B, Kneisel S, Girreser U, Brecht V, Westphal F, Auwärter V (2012) Separation and structural characterization of the synthetic cannabinoids JWH-412 and 1-[(5-fluoropentyl)-1H-indol-3yl]-(4-methylnaphthalen-1-yl)methanone using GC-MS NMR analysis and a flash chromatography system. Forensic Sci Int 220:e17–e22PubMedCrossRef
17.
go back to reference Kneisel S, Westphal F, Bisel P, Brecht V, Broecker S, Auwärter V (2012) Identification and structural characterization of the synthetic cannabinoid 3-(1-adamantoyl)-1-pentylindole as an additive in “herbal incense”. J Mass Spectrom 47:195–200PubMedCrossRef Kneisel S, Westphal F, Bisel P, Brecht V, Broecker S, Auwärter V (2012) Identification and structural characterization of the synthetic cannabinoid 3-(1-adamantoyl)-1-pentylindole as an additive in “herbal incense”. J Mass Spectrom 47:195–200PubMedCrossRef
18.
go back to reference Kneisel S, Bisel P, Brecht V, Broecker S, Müller M, Auwärter V (2012) Identification of the cannabimimetic AM-1220 and its azepane isomer (N-methylazepan-3-yl)-3-(1-naphthoyl)indole in a research chemical and several herbal mixtures. Forensic Toxicol 30:126–134CrossRef Kneisel S, Bisel P, Brecht V, Broecker S, Müller M, Auwärter V (2012) Identification of the cannabimimetic AM-1220 and its azepane isomer (N-methylazepan-3-yl)-3-(1-naphthoyl)indole in a research chemical and several herbal mixtures. Forensic Toxicol 30:126–134CrossRef
19.
go back to reference Huffman JW, Szklennik PV, Almond A, Bushell K, Selley DE, He H, Cassidy MP, Wiley JL, Martin BR (2005) 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett 15:4110–4113PubMedCrossRef Huffman JW, Szklennik PV, Almond A, Bushell K, Selley DE, He H, Cassidy MP, Wiley JL, Martin BR (2005) 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett 15:4110–4113PubMedCrossRef
20.
go back to reference Atwood BK, Huffman J, Straiker A, Mackie K (2010) JWH018, a common constituent of “Spice” herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. Br J Pharmacol 160:585–593PubMedCrossRef Atwood BK, Huffman J, Straiker A, Mackie K (2010) JWH018, a common constituent of “Spice” herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. Br J Pharmacol 160:585–593PubMedCrossRef
21.
go back to reference Atwood BK, Lee D, Straiker A, Widlanski TS, Mackie K (2011) CP47,497-C8, and JWH073, commonly found in “Spice” herbal blends, are potent and efficacious CB(1) cannabinoid receptor agonists. Eur J Pharmacol 659:139–145PubMedCentralPubMedCrossRef Atwood BK, Lee D, Straiker A, Widlanski TS, Mackie K (2011) CP47,497-C8, and JWH073, commonly found in “Spice” herbal blends, are potent and efficacious CB(1) cannabinoid receptor agonists. Eur J Pharmacol 659:139–145PubMedCentralPubMedCrossRef
22.
go back to reference Wiley JL, Marusich JA, Martin BR, Huffman JW (2012) 1-Pentyl-3-phenylacetylindoles and JWH-018 share in vivo cannabinoid profiles in mice. Drug Alcohol Depend 123:148–153PubMedCentralPubMedCrossRef Wiley JL, Marusich JA, Martin BR, Huffman JW (2012) 1-Pentyl-3-phenylacetylindoles and JWH-018 share in vivo cannabinoid profiles in mice. Drug Alcohol Depend 123:148–153PubMedCentralPubMedCrossRef
23.
go back to reference Müller H, Sperling W, Köhrmann M, Huttner HB, Kornhuber J, Maler JM (2010) The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr Res 118:309–310PubMedCrossRef Müller H, Sperling W, Köhrmann M, Huttner HB, Kornhuber J, Maler JM (2010) The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr Res 118:309–310PubMedCrossRef
24.
go back to reference Schneir AB, Cullen J, Ly BT (2011) "Spice" girls: synthetic cannabinoid intoxication. J Emerg Med 40:296–299PubMedCrossRef Schneir AB, Cullen J, Ly BT (2011) "Spice" girls: synthetic cannabinoid intoxication. J Emerg Med 40:296–299PubMedCrossRef
25.
go back to reference Simmons J, Cookman L, Kang C, Skinner C (2011) Three cases of "spice" exposure. Clin Toxicol (Phila) 49:431–433CrossRef Simmons J, Cookman L, Kang C, Skinner C (2011) Three cases of "spice" exposure. Clin Toxicol (Phila) 49:431–433CrossRef
26.
go back to reference Harris CR, Brown A (2013) Synthetic Cannabinoid Intoxication: a case series and review. J Emerg Med 44(2):360–366PubMedCrossRef Harris CR, Brown A (2013) Synthetic Cannabinoid Intoxication: a case series and review. J Emerg Med 44(2):360–366PubMedCrossRef
28.
go back to reference Tung CK, Chiang TP, Lam M (2012) Acute mental disturbance caused by synthetic cannabinoid: a potential emerging substance of abuse in Hong Kong. East Asian Arch Psychiatry 22:31–33PubMed Tung CK, Chiang TP, Lam M (2012) Acute mental disturbance caused by synthetic cannabinoid: a potential emerging substance of abuse in Hong Kong. East Asian Arch Psychiatry 22:31–33PubMed
29.
go back to reference McQuade D, Hudson S, Dargan PI, Wood DM (2012) First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201. Eur J Clin Pharmacol 69(3):373–376PubMedCrossRef McQuade D, Hudson S, Dargan PI, Wood DM (2012) First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201. Eur J Clin Pharmacol 69(3):373–376PubMedCrossRef
30.
go back to reference Cohen J, Morrison S, Greenberg J, Saidinejad M (2012) Clinical presentation of intoxication due to synthetic cannabinoids. Pediatrics 129:e1064–e1067PubMedCrossRef Cohen J, Morrison S, Greenberg J, Saidinejad M (2012) Clinical presentation of intoxication due to synthetic cannabinoids. Pediatrics 129:e1064–e1067PubMedCrossRef
31.
go back to reference Every-Palmer S (2011) Synthetic cannabinoid JWH-018 and psychosis: an explorative study. Drug Alcohol Depend 117:152–157PubMedCrossRef Every-Palmer S (2011) Synthetic cannabinoid JWH-018 and psychosis: an explorative study. Drug Alcohol Depend 117:152–157PubMedCrossRef
32.
go back to reference Benford DM, Caplan JP (2011) Psychiatric sequelae of Spice, K2, and synthetic cannabinoid receptor agonists. Psychosomatics 52:295PubMedCrossRef Benford DM, Caplan JP (2011) Psychiatric sequelae of Spice, K2, and synthetic cannabinoid receptor agonists. Psychosomatics 52:295PubMedCrossRef
33.
go back to reference Gunderson EW, Haughey HM, It-Daoud N, Joshi AS, Hart CL (2012) "Spice" and "K2" herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. Am J Addict 21:320–326PubMedCrossRef Gunderson EW, Haughey HM, It-Daoud N, Joshi AS, Hart CL (2012) "Spice" and "K2" herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. Am J Addict 21:320–326PubMedCrossRef
34.
go back to reference Forrester MB, Kleinschmidt K, Schwarz E, Young A (2011) Synthetic cannabinoid exposures reported to Texas poison centers. J Addict Dis 30:351–358PubMedCrossRef Forrester MB, Kleinschmidt K, Schwarz E, Young A (2011) Synthetic cannabinoid exposures reported to Texas poison centers. J Addict Dis 30:351–358PubMedCrossRef
35.
go back to reference Forrester MB (2012) Adolescent synthetic cannabinoid exposures reported to Texas poison centers. Pediatr Emerg Care 28:985–989PubMedCrossRef Forrester MB (2012) Adolescent synthetic cannabinoid exposures reported to Texas poison centers. Pediatr Emerg Care 28:985–989PubMedCrossRef
36.
go back to reference Hermanns-Clausen M, Kneisel S, Szabo B, Auwärter V (2013) Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction 108(3):534–544PubMedCrossRef Hermanns-Clausen M, Kneisel S, Szabo B, Auwärter V (2013) Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction 108(3):534–544PubMedCrossRef
37.
go back to reference Kneisel S, Auwärter V (2012) Analysis of 30 synthetic cannabinoids in serum by liquid chromatography-electrospray ionization tandem mass spectrometry after liquid-liquid extraction. J Mass Spectrom 47:825–835PubMedCrossRef Kneisel S, Auwärter V (2012) Analysis of 30 synthetic cannabinoids in serum by liquid chromatography-electrospray ionization tandem mass spectrometry after liquid-liquid extraction. J Mass Spectrom 47:825–835PubMedCrossRef
38.
go back to reference McGuinness TM, Newell D (2012) Risky recreation: synthetic cannabinoids have dangerous effects. J Psychosoc Nurs Ment Health Serv 50:16–18PubMedCrossRef McGuinness TM, Newell D (2012) Risky recreation: synthetic cannabinoids have dangerous effects. J Psychosoc Nurs Ment Health Serv 50:16–18PubMedCrossRef
39.
go back to reference Hu X, Primack BA, Barnett TE, Cook RL (2011) College students and use of K2: an emerging drug of abuse in young persons. Subst Abuse Treat Prev Policy 6:16PubMedCentralPubMedCrossRef Hu X, Primack BA, Barnett TE, Cook RL (2011) College students and use of K2: an emerging drug of abuse in young persons. Subst Abuse Treat Prev Policy 6:16PubMedCentralPubMedCrossRef
40.
go back to reference Vearrier D, Osterhoudt KC (2010) A teenager with agitation: higher than she should have climbed. Pediatr Emerg Care 26:462–465PubMedCrossRef Vearrier D, Osterhoudt KC (2010) A teenager with agitation: higher than she should have climbed. Pediatr Emerg Care 26:462–465PubMedCrossRef
41.
go back to reference Seely KA, Lapoint J, Moran JH, Fattore L (2012) Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry 39:234–243PubMedCrossRef Seely KA, Lapoint J, Moran JH, Fattore L (2012) Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry 39:234–243PubMedCrossRef
42.
go back to reference Hoyte CO, Jacob J, Monte AA, Al-Jumaan M, Bronstein AC, Heard KJ (2012) A characterization of synthetic cannabinoid exposures reported to the national poison data system in 2010. Ann Emerg Med 60:435–438PubMedCrossRef Hoyte CO, Jacob J, Monte AA, Al-Jumaan M, Bronstein AC, Heard KJ (2012) A characterization of synthetic cannabinoid exposures reported to the national poison data system in 2010. Ann Emerg Med 60:435–438PubMedCrossRef
43.
go back to reference Castellanos D, Singh S, Thornton G, Avila M, Moreno A (2011) Synthetic cannabinoid use: a case series of adolescents. J Adolesc Health 49:347–349PubMedCrossRef Castellanos D, Singh S, Thornton G, Avila M, Moreno A (2011) Synthetic cannabinoid use: a case series of adolescents. J Adolesc Health 49:347–349PubMedCrossRef
44.
go back to reference Hutter M, Ippisch J, Schultis H-W, Auwärter V (2012) Evaluation of an ELISA for synthetic cannabinoids applied to urine samples by comparison with a comprehensive and highly sensitive LC-MS/MS method. Rechtsmed 22(4):286–287 Hutter M, Ippisch J, Schultis H-W, Auwärter V (2012) Evaluation of an ELISA for synthetic cannabinoids applied to urine samples by comparison with a comprehensive and highly sensitive LC-MS/MS method. Rechtsmed 22(4):286–287
45.
go back to reference Elliott S (2011) Cat and mouse: the analytical toxicology of designer drugs. Bioanalysis 3:249–251PubMedCrossRef Elliott S (2011) Cat and mouse: the analytical toxicology of designer drugs. Bioanalysis 3:249–251PubMedCrossRef
46.
47.
go back to reference Hudson S, Ramsey J, King L, Timbers S, Maynard S, Dargan PI, Wood DM (2010) Use of high-resolution accurate mass spectrometry to detect reported and previously unreported cannabinomimetics in "herbal high" products. J Anal Toxicol 34:252–260PubMedCrossRef Hudson S, Ramsey J, King L, Timbers S, Maynard S, Dargan PI, Wood DM (2010) Use of high-resolution accurate mass spectrometry to detect reported and previously unreported cannabinomimetics in "herbal high" products. J Anal Toxicol 34:252–260PubMedCrossRef
48.
go back to reference Hutter M, Broecker S, Kneisel S, Auwärter V (2012) Identification of the major urinary metabolites in man of seven synthetic cannabinoids of the aminoalkylindole type present as adulterants in “herbal mixtures” using LC-MS/MS techniques. J Mass Spectrom 47:54–65PubMedCrossRef Hutter M, Broecker S, Kneisel S, Auwärter V (2012) Identification of the major urinary metabolites in man of seven synthetic cannabinoids of the aminoalkylindole type present as adulterants in “herbal mixtures” using LC-MS/MS techniques. J Mass Spectrom 47:54–65PubMedCrossRef
Metadata
Title
Driving under the influence of synthetic cannabinoids (“Spice”): a case series
Authors
Frank Musshoff
Burkhard Madea
Gerhard Kernbach-Wighton
Wolfgang Bicker
Stefan Kneisel
Melanie Hutter
Volker Auwärter
Publication date
01-01-2014
Publisher
Springer Berlin Heidelberg
Published in
International Journal of Legal Medicine / Issue 1/2014
Print ISSN: 0937-9827
Electronic ISSN: 1437-1596
DOI
https://doi.org/10.1007/s00414-013-0864-1

Other articles of this Issue 1/2014

International Journal of Legal Medicine 1/2014 Go to the issue